Precision Medicine for Nasopharyngeal Cancer—A Review of Current Prognostic Strategies
Open Access
Abstract
Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV) driven malignancy arising from the nasopharyngeal epithelium. Current treatment strategies depend on the clinical stage of the disease, including the extent of the primary tumour, the extent of nodal disease, and the presence of distant metastasis. With the close association of EBV infection with NPC development, EBV biomarkers have shown promise in predicting treatment outcomes. Among the omic technologies, RNA and miRNA signatures have been widely studied, showing promising results in the research setting to predict treatment response. The transformation of radiology images into measurable features has facilitated the use of radiomics to generate predictive models for better prognostication and treatment selection. Nonetheless, much of this work remains in the research realm, and challenges remain in clinical implementation.Keywords
Funding Information
- National Medical Research Council (Large Collaborative Grant (OFLCG21Jun-0013), Transition Award (TA20nov-0025))
- National Medical Research Council (Large Collaborative Grant (OFLCG21Jun-0013), Transition Award (TA20nov-0025))
This publication has 129 references indexed in Scilit:
- Can Epstein–Barr virus‐deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?Cancer Medicine, 2022
- The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinomaCancer Communications, 2021
- Long‐term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinomaCancer Medicine, 2020
- Staging of T2 and T3 nasopharyngeal carcinoma: Proposed modifications for improving the current AJCC staging systemCancer Medicine, 2020
- The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching studyCancer Communications, 2020
- Identification of a 7‐microRNA signature in plasma as promising biomarker for nasopharyngeal carcinoma detectionCancer Medicine, 2019
- Proposed modifications and incorporation of plasma Epstein‐Barr virus DNA improve the TNM staging system for Epstein‐Barr virus‐related nasopharyngeal carcinomaCancer, 2018
- Dynamic changes in plasma Epstein–Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective studyCancer Medicine, 2018
- Comparison of plasma Epstein–Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinomaCancer, 2004
- Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisationInternational Journal of Cancer, 1999